ProKidney Corp. (PROK)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Operating profit | $m | -165 | -177 | ||||||
| Net profit | $m | -27 | -55 | -108 | -35 | -61 | -69 | -87 | -88 |
| EPS reported | $ | -0.52 | -0.57 | ||||||
| Operating cashflow per share | $ | -0.90 | -0.76 | ||||||
| Capex per share | $ | 0.11 | 0.10 | ||||||
| FCF per share | $ | -1.01 | -0.86 | ||||||
| Free cash flow | $m | -135 | -160 | ||||||
| Net debt | $m | -270 | -180 | ||||||
| Book value equity | $m | -1,011 | -884 | ||||||
| Book value per share | $ | -7.55 | -4.74 | ||||||
| Number of shares | m | 133.94 | 186.56 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.67 | -0.77 | ||||||
| P/S LTM | x | 762.49 | 832.40 | ||||||
| P/FCF LTM | x | -5.03 | -4.26 | ||||||
| EV/EBITDA LTM | x | -3.99 | -3.59 | ||||||
| EV/Sales LTM | x | 645.46 | 458.12 | ||||||
| Earnings Yield LTM | % | -22.99% | -34.94% | ||||||
| FCF Yield | % | -19.87% | -23.46% | ||||||
| Quality | |||||||||
| ROE | % | +6.82% | +12.30% | ||||||
| ROIC | % | -53.94% | -68.08% | ||||||
| Operating margin | % | -184.78% | -216.65% | ||||||
| Gross margin | % | +100.00% | -2.53% | ||||||
| FCF/Sales | % | -15152.6% | -19527.4% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +1075.0% | +976.32% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -33.53 | -45.34 | ||||||
| Net Debt/EBITDA | x | 0.72 | 0.45 | ||||||
| EBIT/Net interest | x | -41,251.75 | -9,327.16 | ||||||
| Net debt/market cap | % | 0.00% | +0.24% | ||||||
| Net debt/Equity | x | 0.27 | 0.20 | ||||||
| Gross debt/equity | x | -0.00 | -0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free